Media Release Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off. Read More Video – The future of Novartis Our future is as a leading focused medicines company, powered by data science and advanced therapy platforms. CEO Vas Narasimhan shares our vision. Video of The future of Novartis Vas on Instagram
View this post on Instagram In the life of a leader and in business, change is constant. With your purpose as your guiding light, you continuously have to iterate and evolve to meet the changing needs around you. That is a lesson I learned early on in my career, and it changed not only my career trajectory but also the way I see the world. Today is a big day for Novartis and for me personally as CEO. When I took over as CEO last year, I challenged our entire company to reimagine Novartis for the future. We set a vision to become a more focused medicines company powered by data science and advanced therapy platforms – and today, with the spin-off of Alcon, our former eye-care devices unit, we’ve taken a major step toward realizing that vision. Novartis is now better positioned than we ever have been to reimagine medicine for patients all around the world. The spin-off allows us to focus our energy on innovating the latest advancements to transform human health, and I’m excited for our associates, for our investors, and most importantly, for patients because of the impact that we could have. ⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀ #reimaginingmedicine #ReimaginingNovartis #OneNovartis #Novartislife ⠀⠀⠀⠀⠀⠀⠀⠀⠀ #speech #speaking #amazing #bestoftheday #happy #inspiration #work ⠀⠀⠀⠀⠀⠀⠀⠀⠀ @novartis A post shared by Vas Narasimhan (@vasnarasimhan) on Apr 9, 2019 at 2:37am PDT In Pictures Alcon lists on the SIX Swiss Exchange and New York Stock Exchange (NYSE)
Novartis CFO Harry Kirsch and Alcon Chairman Mike Ball at the SIX Swiss Exchange in Zürich. NYSE tweeted pictures of the Alcon team in New York Alcon is officially trading on the NYSE
CEO David Endicott rings the Opening Bell and First Trade Bell to mark the occasion pic.twitter.com/aT8V94gh2Z — NYSE (@NYSE) April 9, 2019 Additional Resources Novartis Ophthalmology franchise New Alcon website TwitterTweet FacebookShare Share Twitter Facebook Pinterest LinkedIn Email Whatsapp Jump to Comments Print Save Contact Media Relations For media and journalist inquiries, please contact the Novartis Corporate Media Relations office by email.
Link zum Originalbeitrag